Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib plus chemotherapy for FLT3-mutated acute myeloid leukemia
2013-000501-22Phase 2Terminated
- Sponsor
- Cardiff University
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute myeloid leukemia (AML), sponsored by Cardiff University. Primary endpoint: Relapse-free survival at 12 months. Started Aug 2013; status: terminated.
02
Drugs
ponatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2013-000501-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000501-22.